title: Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: The French SFRO-FFCD 97-04 Phase II trial.
abstract: OBJECTIVE
  More than 80% of patients who undergo a potentially curative resection for pancreatic cancer develop local or distant recurrence. Neoadjuvant chemoradiotherapy might offer potential benefits regarding local and systemic control and survival. This multi-institutional Phase II trial explored the feasibility of preoperative chemoradiation in this situation.
  
  
  METHODS
  Treatment consisted of concurrent radiotherapy (50 Gy within 5 weeks), and chemotherapy with 5-fluorouracil (300 mg/m(2)/day, 5 days/week, 5 consecutive weeks) and cisplatin (20 mg/m(2)/day, Days 1-5 and 29-33), followed by surgical resection of the pancreatic tumor in patients without progression.
  
  
  RESULTS
  A total of 41 patients were enrolled. Of these, 38 (93%) received > or =47 Gy; 30 patients (73%) received > or =75% of the prescribed doses of chemotherapy. Surgical resection was performed in 26 patients (63%). Because of local or metastatic progression, 5 patients (12%) did not undergo surgery and 10 underwent surgery without resection of the pancreatic tumor. Operative mortality was 2.8%. Among 40 evaluable patients, 27 were successfully treated (67.5%; 95% CI, 50.9-81.4%).
  
  
  CONCLUSIONS
  Pancreatic cancer is chemo-radiosensitive. The proposed pre-operative scheme is feasible, does not prevent successful surgery, and must be tested on a Phase III setting. Yet, the large proportion of tumor progression during and after chemoradiation justifies the use of more efficient drugs such as Gemcitabine, and optimized radiotherapy including new techniques such as intensity-modulated radiation therapy.
authors.affiliation: Département de Radiothérapie-Oncologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Lyon France. francoise.mornex@chu-lyon.fr
authors.forename: Françoise
authors.initials: F
authors.lastname: Mornex
authors.forename: Nicolas
authors.initials: N
authors.lastname: Girard
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Scoazec
authors.forename: Nadine
authors.initials: N
authors.lastname: Bossard
authors.forename: Marc
authors.initials: M
authors.lastname: Ychou
authors.forename: Denis
authors.initials: D
authors.lastname: Smith
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Seitz
authors.forename: Pierre-Jean
authors.initials: PJ
authors.lastname: Valette
authors.forename: Pascal
authors.initials: P
authors.lastname: Roy
authors.forename: Philippe
authors.initials: P
authors.lastname: Rouanet
authors.forename: Michel
authors.initials: M
authors.lastname: Ducreux
authors.forename: Christian
authors.initials: C
authors.lastname: Partensky
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy / Q000379:methods; D005240:Feasibility Studies; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D016896:Treatment Outcome
chemical_list: D002945:Cisplatin; D005472:Fluorouracil